Advertised Role
Consumer infant physiologic monitor websites avoid direct statements that their products diagnose, treat, or prevent disease, yet their advertised role is to alert parents when something is wrong with their infants' cardiorespiratory health. In a video featured on the front page of the Owlet website, the company's chief executive officer states, "We can't promise to prevent Sudden Infant Death Syndrome (SIDS) right now, it's an unknown issue but…we believe notifying parents when something's wrong maybe can help."
2 Contrasting its product to audio monitors, a central focus of Baby Vida's advertising is the question "What sound does your baby make if he or she stops breathing?," suggesting that its sock-based pulse oximeter "should be used every time your baby could go to sleep." 3 These direct-to-parent advertising strategies may stimulate unnecessary fear, uncertainty, and selfdoubt in parents about their abilities to keep their infants safe.
Indications
There are no medical indications for monitoring healthy infants at home. An American Academy of Pediatrics policy statement clearly states "Do not use home cardiorespiratory monitors as a strategy to reduce the risk of SIDS," noting that there are no data that commercial devices designed to monitor infant vital signs reduce the risk of SIDS. 4 In select populations, including premature infants at high risk of recurrent apnea, bradycardia, and hypoxemia, physiologic monitoring may be indicated. In those populations, monitoring devices with certain features like those listed in the Table may eventually be of value, but only if their safety, accuracy, and effectiveness are demonstrated.
Regulation
The makers of consumer infant physiologic monitors have avoided US Food and Drug Administration (FDA) medical device regulation by not making claims that the devices prevent SIDS. One company reportedly intended to sell its products as medical devices and was planning to pursue FDA approval but later changed its mind reportedly because of the time and expense required. 5 Striking a balance between fostering innovation while providing appropriate and efficient regulation in the rapidly expanding mobile medical app market is challenging. The fundamental questions that must be answered about consumer infant physiologic monitors center on their safety, accuracy, and effectiveness. To date, medical apps have a disappointing track record. For example, a recent evaluation of a blood pressure app showed that it falsely reassured nearly 80% of patients with hypertension that their blood pressure was normal. 6 Like the infant monitor makers, the developers claimed their app was not to be used for medical advice.
There are a few potential paths to establishing the safety, accuracy, and effectiveness of consumer infant monitors. The first is for the FDA to step in under existing law. In their 2015 guidance document on mobile medical apps, the FDA provides examples of apps that are the focus of their regulatory oversight and include "apps that transform a mobile platform into a regulated medical device," with breathing frequency monitors, apnea monitors, and oximeters among the device types listed. 7 Based on these regulations, consumer infant physiologic monitors would likely be categorized as FDA device class II and be subject to the 510(k) pathway that requires that the makers demonstrate "substantial equivalence" to a legally marketed device. Alternatively, the clinical research community could evaluate the devices and publish the findings from scientific investigations, either independently or in partnership with patient safety organizations or the device companies. Regardless of the approach, the safety, accuracy, and effectiveness of these devices must be evaluated and shared with physicians and parents to enable them to make informed decisions about the use of these products.
Overdiagnosis
Even if consumer monitors were highly accurate, the clinical appropriateness of monitoring healthy infants would remain in question. By continuously monitoring healthy infants, parents will inevitably experience some alarms for conditions that are not lifethreatening, including false-positive alarms due to motion artifact or other causes, and true-positive alarms for events that are not clinically important. Healthy infants have occasional oxygen desaturations to less than 80% without consequence, 8 and these monitors could increase the risk of overdiagnosis and potential harm if these innocuous events generate alarms. Overdiagnosis occurs when the accurate detection of abnormalities fails to benefit the patient. This is because a single abnormal test-such as a self-resolving desaturation-can trigger a cascade of events. For example, a low pulse oximetry alarm from a consumer monitor could prompt an emergency department visit with laboratory tests, imaging studies, and hospital admission. Rather than reassuring parents, these experiences may generate anxiety and a false assumption that their infant is at risk of dying. These considerations introduce the prospect that using a monitor could indirectly result in harm to infants and their families.
Conclusions
The current market of smartphone apps integrated with sensors that monitor infants' vital signs are innovative and have potential to improve care. However, their performance characteristics are unknown to the public and there are no medical indications for their use. Until these monitors have been thoroughly evaluated and guidelines for use have been established, the recommendations physicians should give to parents who ask about these products is simple. There is no evidence that consumer infant physiologic monitors are life-saving, and there is potential for harm if parents choose to use them. Child and family advocates should make it clear to the FDA and policy makers that regulatory guidance and research evaluating the safety, accuracy, and effectiveness of these products are needed.
